Conversely, the use of the active site inhibitor z-VRPR-fmk has no effect on lung carcinoma cells, since NF-κB activation and the development of tumorigenic features in this tumor type is regulated by MALT1′s scaffold function. The gene discussed is NFKB1; the disease is lung carcinoma.